Significance of MMP11 and P14(ARF) expressions in clinical outcomes of patients with laryngeal cancer.
Significance of MMP11 and P14(ARF) expressions in clinical outcomes of patients with laryngeal cancer.
复制标题
DOI：
--
复制
发表时间：
2015-09
影响因子：
0.1
通讯作者：
Zufei Li;Shuo Ding;Q. Zhong;Guojun Li;Yang Zhang;Xiaohong Huang
中科院分区：
文献类型：
--
作者：
Zufei Li;Shuo Ding;Q. Zhong;Guojun Li;Yang Zhang;Xiaohong Huang
[背景]探讨基质金属蛋白酶11（MMP 11）和抑癌基因P14（ARF）在喉鳞状细胞癌（LSCC）中的表达与临床病理特征及生存期的关系。方法检测65例喉鳞状细胞癌组织中两种基因的mRNA和蛋白水平。采用对数秩检验和考克斯模型比较各组间的生存率。结果MMP 11和P14（ARF）mRNA在喉鳞癌组织中的表达与癌旁组织相比差异有显著性（P均< 0.001）。ARF中MMP 11和P14的表达与多项临床特征相关（均P < 0.05）。MMP 11低表达、P14高表达（ARF）患者的生存率分别显著高于MMP 11高表达、P14低表达（P均< 0.05）。仅手术患者的生存率显著高于放化疗患者（log rank：P = 0.016），尤其是MMP 11低表达和P14（ARF）高表达的患者（log rank：P = 0.006）。此外，多变量分析显示，与MMP 11高表达和P14低表达（ARF）患者相比，MMP 11低表达和P14高表达（ARF）患者的死亡风险显著降低。与两种基因的任何其他共表达状态相比，两种基因低表达和高表达的患者总体死亡风险降低明显（HR，0.2; 95% CI，0.1-0.5），特别是仅接受手术的患者（HR，0.1; 95% CI，0.0-0.9）。结论MMP 11和P14（ARF）在喉鳞状细胞癌中的表达改变可能单独或联合预测喉鳞状细胞癌的不良预后，特别是对仅行手术治疗的患者。
BACKGROUND To evaluate the association of MMP11 and P14(ARF) expression in laryngeal squamous cell carcinoma (LSCC) with clinical pathological characteristics and survival. METHODS The mRNA and protein levels for both genes were determined in 65 LSCC patients. A log-rank test and Cox models were used to compare survival among different groups. RESULTS The mRNA expressions of MMP11 and P14(ARF) were significantly different between LSCC and their corresponding adjacent tissues (All P < 0.001). The expressions of MMP11 and P14(ARF) were correlated with several clinical characteristics (All P < 0.05). Patients with low MMP11 and high P14(ARF) expression had significantly better survival compared with those with high MMP11 and low P14(ARF) expression, respectively (All P < 0.05). The patients with surgery only had significantly better survival than those with chemoradiotherapy (log rank: P = 0.016), particularly in patients with low MMP11 and high P14(ARF) expression (log rank: P = 0.006). Furthermore, multivariable analysis showed that patients with low MMP11 and high P14(ARF) expression alone had a significantly reduced risk of death compared with those with high MMP11 and low P14(ARF) expression. The reduced risk for overall death was pronounced for patients with low and high expression of both genes (HR, 0.2; 95% CI, 0.1-0.5) compared with any other co-expression status of both genes, particularly for patients with surgery only (HR, 0.1; 95% CI, 0.0-0.9). CONCLUSION These results suggest that altered expression of MMP11 and P14(ARF) in tumors may individually, or in combination, predict poor prognosis of LSCC, particularly for patients with surgery only.